Overcoming the stromal barrier: technologies to optimize drug delivery in pancreatic cancer
- 30 April 2012
- journal article
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 4 (5), 271-279
- https://doi.org/10.1177/1758834012446008
Abstract
Pancreatic cancer has historically proven resistant to anticancer agents. On the one hand, drugs might be more efficient if higher levels could be achieved at the tumor site rather than the normal tissues. On the other hand, the thick stroma and the relative absence of abundant vessels may account at least partially for the failure of successive clinical trials to demonstrate effective treatments in this type of malignancy. In this context, the development and testing in clinical trials of treatment strategies that aim to optimize drug delivery is an important target in improving the prognosis of patients with pancreatic cancer.Keywords
This publication has 46 references indexed in Scilit:
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- Nanoconjugation modulates the trafficking and mechanism of antibody induced receptor endocytosisProceedings of the National Academy of Sciences of the United States of America, 2010
- Inhibition of NFκB and Pancreatic Cancer Cell and Tumor Growth by Curcumin Is Dependent on Specificity Protein Down-regulationJournal of Biological Chemistry, 2010
- Pancreatic CancerNew England Journal of Medicine, 2010
- Half-Antibody Functionalized Lipid−Polymer Hybrid Nanoparticles for Targeted Drug Delivery to Carcinoembryonic Antigen Presenting Pancreatic Cancer CellsMolecular Pharmaceutics, 2010
- Bioconjugation of Calcium Phosphosilicate Composite Nanoparticles for Selective Targeting of Human Breast and Pancreatic Cancers In VivoACS Nano, 2010
- PEG Branched Polymer for Functionalization of Nanomaterials with Ultralong Blood CirculationJournal of the American Chemical Society, 2009
- Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasisProceedings of the National Academy of Sciences of the United States of America, 2008
- Hypoxia and cancerJournal of Molecular Medicine, 2007
- Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-β signalingProceedings of the National Academy of Sciences, 2007